Glimepiride 1 MG +Metformin 500 MG (SR)+Voglibose 0.1 MG Tablets – GLANIL MV1 Tablets

GLANIL MV1 Tablets – Triple Action Formula for Type 2 Diabetes Management.

GLANIL MV1 Tablets – The Triple combination of Glimepiride 1 MG + Metformin 500 MG (SR) + Voglibose 0.1 MG Tablets combines Glimepiride, Voglibose, and Metformin, each with distinct mechanisms to effectively control blood glucose levels in patients with type 2 diabetes mellitus.
Glimepiride, a sulfonylurea, enhances insulin secretion from the pancreas.
Voglibose, an alpha-glucosidase inhibitor, slows carbohydrate absorption in the intestines, specifically helping with postprandial glucose control.
Metformin, a biguanide, improves insulin sensitivity, decreases hepatic glucose production, and enhances peripheral glucose uptake. The extended-release (ER) formulation of Metformin ensures a prolonged, steady effect throughout the day.

Key Benefits of Glimepiride + Metformin (SR) + Voglibose Tablets – GLANIL MV1 Tablets
✅Triple Mechanism of Action – This combination targets three different pathways—pancreatic insulin release, carbohydrate absorption, and insulin sensitivity—for enhanced blood glucose control.
✅Comprehensive Glycemic Management – The combination addresses both fasting and postprandial blood glucose, with Voglibose specifically helping to control post-meal spikes.
✅Extended-Release Metformin – The ER formulation of Metformin provides sustained blood glucose control with reduced gastrointestinal side effects, allowing once-daily dosing and improved patient adherence.

Recommended By Specialists:
👨‍⚕️Endocrinologists: Mainly prescribed to manage complex or poorly controlled Type 2 Diabetes cases.
👨‍⚕️General Physicians: Helpful in managing mild diabetes and maintaining long-term glycemic control.

INDICATION:
✅ Type 2 Diabetes Mellitus
✅ Postprandial Hyperglycemia
✅ Prevention of Long-Term Complications